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We identified a 26-amino-acid truncated form of the 34-amino-acid cathelicidin-related antimicrobial peptide (CRAMP) in the
islets of Langerhans of the murine pancreas. This peptide, P318, shares 67% identity with the LL-37 human antimicrobial pep-
tide. As LL-37 displays antimicrobial and antibiofilm activity, we tested antifungal and antibiofilm activity of P318 against the
fungal pathogen Candida albicans. P318 shows biofilm-specific activity as it inhibits C. albicans biofilm formation at 0.15M
without affecting planktonic survival at that concentration. Next, we tested the C. albicans biofilm-inhibitory activity of a series
of truncated and alanine-substituted derivatives of P318. Based on the biofilm-inhibitory activity of these derivatives and the
length of the peptides, we decided to synthesize the shortened alanine-substituted peptide at position 10 (AS10; KLKKIAQKIKN
FFQKLVP). AS10 inhibited C. albicans biofilm formation at 0.22M and acted synergistically with amphotericin B and caspo-
fungin against mature biofilms. AS10 also inhibited biofilm formation of different bacteria as well as of fungi and bacteria in a
mixed biofilm. In addition, AS10 does not affect the viability or functionality of different cell types involved in osseointegration
of an implant, pointing to the potential of AS10 for further development as a lead peptide to coat implants.
In natural environments such as the human body, fungal andbacterial species are typically found in biofilms. The latter are
well-structured populations of microbial cells attached to a sur-
face and embedded in a self-produced polymer matrix (1, 2). Bio-
films can be formed on natural body surfaces or on medical de-
vices, including urinary and vascular catheters, implants,
prostheses, and heart valves (3, 4). These biofilms are of great
significance for public health, as they are critical in the develop-
ment of clinical infections and are frequently refractory to con-
ventional antimicrobial agents (5). The cause of this increased
resistance is not yet fully understood but could be due to a com-
bination of different mechanisms, including (i) expression of re-
sistance genes, (ii) binding of the antimicrobials to the extracellu-
lar matrix, (iii) alteration in microbial membrane composition,
and (iv) presence of microbial persister cells, which are cells that
are transiently tolerant of high doses of an antimicrobial agent (6).
Most pathogens, including Candida species (3), Pseudomonas
aeruginosa, Escherichia coli (7), and Porphyromonas gingivalis (8),
can cause biofilm-associated infections. Several species of the ge-
nus Candida, including C. albicans, C. glabrata, C. krusei, and C.
dubliniensis, are opportunistic human fungal pathogens that may
cause life-threatening systemic infections, particularly in immu-
nocompromised patients. P. aeruginosa and E. coli are important
opportunistic bacteria involved in several infections, including
persistent airway infections in cystic fibrosis patients and urinary
tract infections, respectively (9, 10). The Gram-negative oral an-
aerobe P. gingivalis is involved in the pathogenesis of periodontitis
(8).
Most of the currently available antifungals and antibiotics are
unable to cure these biofilm-associated infections effectively (11,
12). Therefore, treatment often requires the removal of the in-
fected device, which can be an expensive and painful surgical pro-
cedure. Hence, new compounds with potent antibiofilm activity,
preferentially active against both fungal and bacterial biofilms, are
urgently needed. Apart from the systemic administration of anti-
biofilm compounds to cure biofilm-associated infections, such
molecules can be used as a coating on, e.g., medical devices,
thereby preventing biofilm formation by microbial pathogens on
the device and thus resulting in a reduced risk for development of
biofilm-associated device infections. Current antibiofilm coatings
ofmedical devices aremainly based on the use of silver ions, which
can be toxic to the host upon accumulation (13), or on the release
of standard antibiotics or antifungal agents for which biofilms
display increased resistance.
Cationic antimicrobial host defense peptides represent a
promising class of antimicrobials and are ubiquitous in nature as
components of innate immune defense systems (14–16). More-
over, they are widely regarded as a potential source of future an-
tibiotics owing to a remarkable set of advantageous properties
ranging from a broad spectrum of activity to a low propensity for
resistance development (17). The major human cationic host de-
fense peptide is LL-37 (Table 1). In addition to its key role in
modulating the innate immune response and antimicrobial activ-
ity, LL-37 potently inhibits the biofilm formation of severalGram-
negative and Gram-positive bacterial species (16, 23–25). Devel-
opment of P. aeruginosa biofilms is inhibited in vitro at low (1
g/ml) LL-37 concentrationswhich are at least 100-fold below the
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concentration required to kill or inhibit bacterial growth (16).
Apparently, LL-37 affects biofilm formation by decreasing the at-
tachment of bacterial cells and by downregulating genes essential
for biofilm development (16). A structure-activity analysis of the
effect of LL-37 on bacterial biofilm formation showed that peptide
fragments of LL-37 are able to inhibit biofilm formation at sub-
bactericidal concentrations without displaying cellular toxicity
(18, 19). A 25-amino-acid (aa)-long LL-37 derivative, LL7-31 (Ta-
ble 1), was found to possess antibacterial and antibiofilm activities
against P. aeruginosa without showing cytotoxicity (19). Further
shortening of the LL-37 backbone to a 20-aa fragment resulted in
KR20, still exhibiting bacterial antibiofilm activity (21). Apart
from antibacterial activity, LL-37, as well as truncated versions
LL13-37 and LL17-32, is able to inhibit planktonic growth of the
human fungal pathogenC. albicans.Wong and colleagues showed
that LL13-37 permeabilizes the Candida cell membrane and in-
duces the production of reactive oxygen species (20). LL-37 also
inhibits adhesion of C. albicans to plastics and tissues by interact-
ing with yeast cell wall carbohydrates (26) and elevating the-1,3-
exoglucanase activity of Xog1 (27). All these data point to poten-
tial activity of LL-37 against formation of C. albicans biofilms, as
adhesion is an important step in this process. However,C. albicans
antibiofilm activity of LL-37 has never been directly demon-
strated.
In the present study, we developed a shortened variant of
mouse LL-37, termed AS10, which was characterized by potent
antibiofilm activity against C. albicans and against various bacte-
rial species, including E. coli, P. aeruginosa, and P. gingivalis. In
light of its potential application as an antibiofilm coating onmed-
ical devices and implants, the absence of cytotoxicity of AS10 and
its effect on functionality of human osteoblasts, mesenchymal
stromal cells, and endothelial cells were investigated.
MATERIALS AND METHODS
Strains and chemicals. Strains C. albicans SC5314 (28), C. albicans
DAY286 (29), C. albicans CAF2-1 (28), C. glabrata BG2 (30), C. krusei
IHEM6104 (Belgian Co-ordinated Collections of Microorganisms
[BCCM], Antwerp, Belgium), C. dubliniensis NCPF3949 (31), Staphylo-
coccus epidermidis (32), E. coli TG1 (33), P. aeruginosa PA14 (34), and P.
gingivalisATCC 33277 (35) were used in this study. Overnight cultures of
C. albicans were grown in YPD (1% yeast extract, 2% peptone, and 2%
dextrose) at 30°C. Overnight cultures of S. epidermidis, P. aeruginosa, and
P. gingivalis were grown in TSB (3% Trypticase soy broth) at 37°C. Over-
night cultures of E. coli were grown in lysogeny broth (LB) medium at
37°C. RPMI 1640 medium with L-glutamine and without sodium bicar-
bonate was purchased from Sigma and buffered to pH 7.0 with MOPS
(morpholinepropanesulfonic acid; Sigma, St. Louis, MO) (final concen-
tration, 165 mM). Stock solutions of caspofungin acetate (Cancidas;
Merck, Beeston Nottingham, United Kingdom) and amphotericin B
(Sigma, St. Louis, MO) were prepared in dimethyl sulfoxide (DMSO).
Phosphate-buffered saline (PBS) was prepared by combining 8 g liter1
NaCl, 0.291 g liter1 KCl, 1.44 g liter1 Na2HPO4, and 0.24 g liter
1
KH2PO4 (pH7.4). All P318-derived peptides were synthesized by Thermo
Scientific (Ulm, Germany) at a purity of at least 95% as determined by
liquid chromatography (LC) and mass spectrometry (MS). All peptides
were stored as a 3 mM stock solution in 70% acetonitrile at20°C. Suit-
able aliquots were dried in a Speedvac concentrator (Savant) and were
dissolved in MilliQ water before use.
Fungicidal activity against C. albicans cells. The MFC-2 (the mini-
mal fungicidal concentration that kills 50% of planktonic C. albicans cells
relative to the growth control) of AS10 was determined. To this end,
2-fold serial dilution series of AS10 were prepared in MilliQ water and
subsequently diluted 10-fold in RPMI 1640. Next, 5-l volumes of these
dilutions were transferred to the wells of a flat-bottomed 96-well micro-
titer plate. A 5-l volumeofMilliQwaterwas used as a control. Afterward,
95l of an overnight culture ofC. albicans, diluted to an optical density at
600 nm (OD600) of 0.1 in RPMI 1640, was added to the wells. After 24 h of
static incubation at 37°C, viability of the cells was assessed by plating on
YPD agar plates. Afterward, the number of CFU was counted and the
percentage of surviving cells relative to the control treatment was calcu-
lated.
Antibiofilm assay: inhibition or eradication of Candida biofilms
grown on polystyrenemicrotiter plates.The potential of the peptides for
inhibition of Candida biofilm formation was assessed using the cell titer
blue (CTB) quantification method (36) or the 2,3-bis(2-methoxy-4-ni-
tro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hy-
droxide (XTT) assay (37). To this end, an overnight culture of Candida
was washed with PBS and a cell suspension of 106 cells/ml was prepared in
RPMI 1640 medium (pH 7.0). Two-fold serial dilution series of the pep-
tides (dissolved in MilliQ water) were prepared in RPMI medium. Five-
microliter volumes of these series were added with 95 l of inoculum to
each well of a round-bottomed polystyrene 96-well microtiter plate (TPP,
Trasadingen, Switzerland). After 24 h of static incubation at 37°C, bio-
films were washed and quantified as described before (38, 39). Activity of
AS10 against biofilms of C. glabrata, C. dubliniensis, and C. krusei was
assessed with the XTT assay (38, 39). The percentage of fluorescence/
absorbance, which correlates with metabolically active biofilm cells, was
calculated relative to the control treatment level. BIC-2 and BIC-5 are
defined as the minimal concentrations of a compound resulting in 2- and
5-fold decreases in biofilm formation relative to the control treatment
level, respectively. Data represent the means and standard errors of the
TABLE 1 LL-37 derivatives and CRAMP derivatives and their antibiofilm activitya
Peptide Sequence AB
Reference or
source
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES  18
LL-31 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNL------  18
LL7-31 ------RKSKEKIGKEFKRIVQRIKDFLRNL------  19
LL17-32 ----------------FKRIVQRIKDFLRNLV----- ND 20
LL13-37 -------------GKEFKRIVQRIKDFLRNLVPRTES ND 20
KS30 -------KSKEKIGKEFKRIVQRIKDFLRNLVPRTES  21
KR20 -----------------KRIVQRIKDFLRNLVPRTES  21
CRAMP ---GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ ND 22
CRAMP-18 -------------GEKLKKIGQKIKNFFQKL------ ND 22
P318 -----------KIGEKLKKIGQKIKNFFQKLVPQPEQ This study
AS10 ---------------KLKKIAQKIKNFFQKLVP---- This study
a AB, reported antibiofilm activity;, antibiofilm activity reported in corresponding reference; ND, not determined. Amino acid residues in bold are conserved.
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means (SEM) of the results of at least 2 experiments, each consisting of 2
technical repeats.
Eradication of fungal biofilms was determined using a previously de-
scribed protocol (39). To this end, 100 l of an overnight culture of C.
albicans, diluted to 106 cells/ml (OD600 0.1) in RPMI 1640medium (pH
7.0), was added to each well of a round-bottom polystyrene 96-well mi-
crotiter plate (TPP, Trasadingen, Switzerland). After 1 h of adhesion at
37°C, nonadherent cells were removed and 100 l of RPMI 1640 was
added to each well. After 24 h of incubation at 37°C, biofilms were washed
with PBS. Two-fold serial dilution series of the peptides were prepared in
RPMI 1640 and added to the biofilms. After 24 h of static incubation at
37°C, biofilms were rinsed with PBS and quantified with CTB as previ-
ously described (38). The percentage of fluorescence, which correlates
withmetabolically active biofilm cells, was determined relative to the con-
trol treatment. The experiment was performed twice, with each experi-
ment consisting of 4 independent technical repeats.
Antibiofilm assay: inhibition of biofilm formation ofC. albicans on
titaniumdisks.Commercially pure titanium sheets (grade 2; Goodfellow,
Huntingdon, United Kingdom) 1 mm in thickness were laser cut into
square discs of 0.64 cm2. Titanium disks were placed in a 24-well plate
(Greiner Bio one, Kremsmünster, Austria), and 500 l of a C. albicans
suspension (106 cells/ml) in RPMI 1640 containing 12.5 or 6.25MAS10
or MilliQ water (control treatment) was added to the wells of the disks.
After an adhesion phase of 1 h, disks were washed with 500 l PBS and
placed in a new microtiter plate. To all the wells, 500 l of fresh RPMI
1640 medium containing 12.5 or 6.25 M AS10 or MilliQ water (0.5%
control treatment) was added. After 24 h of biofilm formation, disks were
washed twice by the addition of 1 ml PBS to the disks. Biofilms were
dissociated from the disks by sonication (10 min) and thorough a vortex
procedure (30 s), which was repeated twice. Finally, cell suspensions were
diluted and plated on YPD agar plates. After 2 days of incubation at 30°C,
CFU were counted. Three biologically independent experiments were
performed consisting of duplicate repeats.
Antibiofilm assay: inhibition of bacterial biofilms.A static peg assay
for the prevention of bacterial biofilm formation was used as described
previously (40, 41). The device used for biofilm formation was a platform
carrying 96 polystyrene pegs (Nunc no. 445497) that fits as a microtiter
plate lid with a peg hanging into each microtiter plate well (Nunc no.
269789). Two-fold serial dilutions of the compounds in 100 l liquid
broth (TSB diluted 1/20) per well were prepared in the microtiter plate (2
repeats per compound). Subsequently, an overnight culture of E. coliTG1
(grown in LBmedium) or P. aeruginosa PA14 (grown in TSB) was diluted
1:100 into the respective liquid broth, and 100 l (106 cells) was added
to each well of the microtiter plate, resulting in a total amount of 200 l
medium per well. P. gingivalis (ATCC 33277) overnight cultures were
grown anaerobically (Anoxomat, AN20°; Mart Microbiology, Drachten,
theNetherlands) in TSB at 37°C, and 100l of a 1	 108 cell suspension in
TSB was added to the wells. Thereafter, the pegged lid was placed on the
microtiter plate and the plate was incubated for 24 h at 37°C without
shaking. Biofilms of P. gingivalis were grown anaerobically. During this
incubation period, biofilms were formed on the surface of the pegs. For
quantification of biofilm formation, the pegs were washed once in 200 l
PBS. The remaining attached bacteria were stained for 30min with 200l
0.1% (wt/vol) crystal violet in an isopropanol-methanol-PBS solution
(1:1:18 [vol/vol]). Excess stain was rinsed off by placing the pegs in a
96-well plate filled with 200l distilled water per well. After the pegs were
air dried (30 min), the dye bound to the adherent cells was extracted with
30% glacial acetic acid (200 l per well of a 96-well plate). The OD570 of
each well was measured using a Synergy MX multimode reader (Biotek,
Winooski, VT). TheBIC-2 value for each compoundwas derived from the
concentration gradient using nonlinear curve fitting (GraphPad Prism 5;
Graphpad Software, Inc., La Jolla, CA). Data represent means
 SEM.
Mixed biofilm assay.Mixed biofilms of C. albicans and S. epidermidis
were grown and quantified as described previously (38). Briefly, biofilms
were grown in the presence or absence of AS10 during both the adhesion
phase and the maturation phase. Afterward, biofilms were quantified us-
ing plating onYPDagar plates containing 100mg/liter ampicillin andTSB
agar plates containing 25 mg/liter amphotericin B. The percentage of C.
albicans and S. epidermidis biofilm cells was determined relative to the
MilliQ water control treatment.
Checkerboard antibiofilm assay. To determine synergistic interac-
tions between AS10 and the antifungal agents caspofungin, amphotericin
B, and miconazole against mature C. albicans biofilms, a checkerboard
analysis was used and fractional inhibitory concentration index (FICI)
values were calculated. The FICI values were calculated by the formula
FICI  [C(BEC-2 A)/BEC-2 A]  [C(BEC-2 B)/BEC-2 B], in which
C(BEC-2A) andC(BEC-2B) are the BEC-2 values of the antifungal agents
in combination and BEC-2 A and BEC-2 B are the BEC-2 values of anti-
fungal agents A and B alone. The BEC-2 is the biofilm-eradicating con-
centrationwhich is theminimal concentration of a compound that results
in a 2-fold eradication of the biofilm relative to the control treatment. The
interaction was defined as synergistic when FICI 0.5, indifferent when
0.5 FICI 4, and antagonistic when FICI 4.0 (42). For these deter-
minations, an overnight culture of C. albicans SC5314 was diluted in
RPMI 1640medium to a cell density of 106 cells/ml. One hundredmicro-
liters of this inoculum was added to the wells of a round-bottom micro-
titer plate (TPP, Trasadingen, Switzerland). After 1 h of adhesion at 37°C,
the medium was aspirated and the biofilms were washed with 100 l PBS
to remove nonadherent cells, followed by the addition of 100 l fresh
RPMI 1640 medium. After 24 h of biofilm development at 37°C, the
biofilms were washed with 100 l PBS, after which 100 l of a combina-
tion of AS10 with caspofungin (0.01 to 5 M), amphotericin B (0.01 to 5
M), ormiconazole (0.2 to 100M), in each case 2-fold serially diluted in
RPMI 1640 medium across the columns and rows of the microtiter plate,
respectively, was added to each well (final DMSO background of 0.1%).
After 24 h of treatment at 37°C, biofilmmass was quantified with the CTB
method as previously described (38). A sub-BEC-2/BEC-5 value of AS10
(400 M) was used to calculate the FICI values, as concentrations as high
as 400MAS10 did not have any effect onmature biofilms (as opposed to
biofilm formation). FICI values for the AS10-caspofungin/amphotericin
B interaction of 3 independent experiments are shown.
Mammalian-cell viability assay. Cell viability of three human pri-
mary cell cultures, namely, osteoblasts, mesenchymal stromal cells, and
microvascular endothelial cells, was tested with trypan blue staining ac-
cording to the ISO 10993-5 standard, as previously described (39). Briefly,
cells were seeded at 2	 104 cells/cm2 in 96-well tissue culture test plates
(TPP, Switzerland) and were exposed in 4 replicates to (i) medium, (ii)
medium with 0.05% phenol (cytotoxic control), and (iii) medium with
AS10 (12.5 M). After 6 days of culture, the cell culture medium was
removed from the 96wells and a 1/3 dilution of trypan blue stock (0.4%)–
Dulbecco’s modified Eagle’s medium (DMEM) was added to the culture
for 3min.Dead (blue) and live (transparent) cells were counted in 2 visual
fields for each of the four replicates.
Endothelial tube formation assay. Tube formation was determined
as previously described (39). Briefly, human aortic endothelial cells were
cultured in M200 medium with low-serum growth supplement (all from
Gibco, Carlsbad, CA). A 24-well plate was coated with 250 l of phenol-
red-freeMatrigel (Becton, Dickinson, Bedford,MA) per well, and human
aortic endothelial cells were seeded at 2	 104 cells/cm2. Themediumwas
supplemented with phenol (0.05%) or AS10 (12.5 M). Nonsupple-
mented medium was used as the control. Eight hours after seeding of the
cells, 3 random phase-contrast digital images in each of the 3 wells per
treatment were taken. Tube-like structures were analyzed with ImageJ
software (http://rsbweb.nih.gov/ij/), and average tube length per field was
calculated.
Osteogenic differentiation. The effect of peptides on osteogenic dif-
ferentiation potential was assessed as previously described (39). Briefly,
osteoblasts and mesenchymal stromal cells were cultured in osteogenic
medium without or with 12.5 M AS10. Osteoblast and mesenchymal
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stromal cell cultures were harvested after 3 or 5 weeks for the calcium and
DNA assay.
Calcium andDNA assay.Calcium deposition of osteoblasts andmes-
enchymal stromal cells was measured with the Calcium CPC LiquiColor
test (Stanbio Laboratory, Boerne, TX) as previously described (39).
Briefly, cell cultures were extracted with 5% trichloroacetic acid (500 l
per sample), O-cresolphtalein complex one was added, and the calcium
content was determined spectrophotometrically at 550 nm. DNA content
was determined as previously described (39). DNA values were used to
normalize calcium content. Four wells per condition were examined, and
two samples from each well were taken for each assay.
Statistical analysis. The statistical significance of the results from the
above-described cell assays was tested with one-way analysis of variance
(ANOVA) followed by Tukey’s test. P values  0.05 were considered
statistically significant.
RESULTS AND DISCUSSION
Inhibition of C. albicans biofilm formation by P318 and P318
sequence variants.The Section of Animal Physiology andNeuro-
biology (KU Leuven, Belgium) houses a peptide library withmore
than 1,000 putative bioactive peptides that were identified from
different species. P318 (KIGEKLKKIAQKIKNFFAKLVAQPEQ;
Table 1), a shortened variant of the known cathelicidin-related
antimicrobial peptide (CRAMP; Table 1), was recently discovered
in the islets of Langerhans of the murine pancreas (43; Bart Lan-
duyt, Walter Luyten, and Liliane Schoofs, personal communica-
tion). As CRAMP shares 67% sequence identity with the LL-37
human antimicrobial peptide (Table 1), we assessed the potential
antibiofilm activity of P318 againstC. albicans using themetabolic
dye CTB. P318 concentrations as low as 0.15 M decreased bio-
film formation of C. albicans up to 2-fold (BIC-2).
We subsequently performed a structure-activity relationship
study of P318 to identify amino acids important for its antibiofilm
activity. Truncated derivatives of P318 aswell as a series of variants
in which amino acids were individually replaced by alanine were
synthesized, and the corresponding BIC-2 and BIC-5 values of
these P318 derivatives were determined. P318 was identified in
mouse tissue (pancreas) both in unmodified form and in a mod-
ified C-terminal-amidated form. As the latter modification is
known to influence stability and activity, both forms were tested
in this structure-activity relationship. All truncated peptides
showed decreased antibiofilm activity compared to P318, al-
though several peptides still had BIC-2s lower than 0.3M(Table
2). For more-stringent selection of the best truncated and se-
quence-modified derivatives, we used an additional parameter,
namely, BIC-5.
Once the peptides reach a certain minimal length, BIC-2 and
BIC-5 values of some P318-derived peptides can drastically in-
crease (Table 2). For example, the BIC-2 values of 318_13, 318_38,
and 318_51 were significantly increased compared to those of the
closely related 318_12, 318_37, and 318_50 peptides, respectively,
which are only 1 aa longer. Note that the biofilm-inhibitory activ-
ity of 318_4 and 318_28 is more than 30-fold decreased compared
to that of the closely related 318 variants which are either 1 aa
shorter or longer (Table 2). The reason for the drastically de-
creased activity of these particular peptides is currently being in-
vestigated. In contrast to most of the P318-derived peptides,
which can inhibit biofilm formation by 50% and 80% at similar
concentrations, peptide 318_35 shows a BIC-2 of 0.30 M but a
BIC-5  25 M. Combining BIC-2 and BIC-5 values with the
minimal length of a peptide showing C. albicans biofilm-inhibi-
tory activity, peptide 318_50, which is 8 aa shorter than P318, has
themost potent biofilm-inhibitory activity, with BIC-2 and BIC-5
values of 0.24 M and 0.38 M, respectively (Table 2).
In parallel, the biofilm-inhibitory activity of variant forms of
P318, in which each amino acid of the native sequence was indi-
vidually replaced by an alanine residue, was determined (Table 3).
Replacement of most of the amino acids did not result in sub-
stantially altered BIC values. However, replacement of the 1st
(318_AS1) or 14th (318_AS14) amino acid with an alanine
resulted in antibiofilm activity that was reduced more than 2-
or 5-fold, respectively, compared to the native P318 sequence
activity (Table 3). These data demonstrate the importance of
the replaced lysines, which is in line with data obtained by Shin
and colleagues (44). They showed that substitution of non-
positively charged residues in CRAMP-18 (Table 1) with
lysines resulted in increased antibacterial and antifungal activ-
ity against planktonic cells. Replacement of the 5th (318_AS5),
10th (318_AS10), or 21st (318_AS21) amino acid by alanine
resulted in BIC-2  0.120 M.
Combining the results obtained in Table 2 and Table 3, we
decided to synthesize peptide P318_50_AS10, here referred to as
AS10. The sequence of this peptide (KLKKIAQKIKNFFQKLVP)
is based on the sequence of peptide 318_50 combined with an
alanine replacement of the glycine in position 6 (position 10 in the
native P318 sequence). P318_50 was chosen as a template based
on its potent antibiofilm activity combined with aminimal length
of the peptide (Table 2). We chose to focus only on the alanine
substitution of the glycine in position 10 of P318 as the other two
alanines (in positions 5 and 21) are at the outer borders of the
AS10 sequence (positions 1 and 17). The BIC-2 and BIC-5 values
of AS10 are 0.22Mand 0.34M, respectively. Thus, by combin-
ing the alanine replacement in position 10 with the P318_50 trun-
cated version, we obtained improved BIC-2- and BIC-5 values
compared to those of P318_50. Note that the amino acid sequence
of AS10 shares 50% identity with the corresponding region of
LL-37 (Table 1).
AS10 specifically inhibits C. albicans biofilm development.
Concentrations of AS10 corresponding to its BIC-2 and BIC-5
values do not affect survival of planktonic C. albicans cells
(MFC-2  50 M). This is in line with observed biofilm inhibi-
tion of P. aeruginosa at low LL-37 concentrations, which are at
least 100-fold below the concentration required to kill or inhibit
planktonic growth (16). Also, the recently identified OSIP108
plant decapeptide inhibits C. albicans biofilm formation at con-
centrations that do not affect viability of C. albicans cells (39). We
also checked if AS10 could inhibit biofilm formation of different
Candida species, including C. glabrata, C. krusei, and C. dublini-
ensis. However, none of the AS10 concentrations used (BIC-2 
100 M) could prevent biofilm formation of these Candida
strains, indicating that AS10 displays C. albicans-specific antibio-
film activity. To investigate whether the observed antibiofilm ac-
tivity of AS10 is strain (SC5314) specific, we also tested other C.
albicans strains such as DAY286 and CAF2-1 (see Table 5). AS10
showed comparable levels of antibiofilm activity against all tested
C. albicans strains. The BIC-2 values of AS10 against biofilms of
DAY286 and CAF2-1 were 0.32
 0.05 M and 0.67
 0.18 M,
respectively, whereas the BIC-2 of AS10 against SC5314 was
0.22
 0.02. To further investigate whether the AS10 antibiofilm
activity is due to interference with the adhesion of planktonic cells
to the polystyrene substrate, we performed additional experi-
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ments (on DAY286) where AS10 was added only after the adhe-
sion phase. The BIC-2 of AS10 in this setup was 0.65
 0.05 M.
The fact that the BIC-2 in the latter setup increased only 2-fold
(compared to 0.32 Mwhen AS10 is present during the adhesion
phase) indicates that AS10 interferes mainly with the biofilm for-
mation process rather than with biofilm adherence. Finally, to
investigate whether AS10 also inhibits C. albicans biofilm forma-
tion on substrates other than polystyrene, we investigated the ac-
tivity of AS10 against biofilm formation ofC. albicans on titanium
disks as a model for implant substrates. To this end, C. albicans
biofilms were grown on titanium disks in the absence or presence
of AS10 (12.5 and 6.25M) for 24 h (Fig. 1). Using CFU determi-
nation, we found that both concentrations of AS10 can signifi-
cantly prevent biofilm formation of C. albicans on titanium disks
(P  0.05). These data indicate that (i) the observed antibiofilm
activity of AS10 is not polystyrene specific and (ii) AS10’s antib-
TABLE 2 Biofilm-inhibitory activity of truncated forms of P318
Peptide Sequence BIC-2 (M)
 SEM BIC-5 (M)
 SEM
P318 [H]KIGEKLKKIGQKIKNFFQKLVPQPEQ[NH2] 0.15
 0.03 0.32
 0.04
318_1 [H]IGEKLKKIGQKIKNFFQKLVPQPEQ[NH2] 0.33
 0.10 7.83
 1.86
318_2 [H]GEKLKKIGQKIKNFFQKLVPQPEQ[NH2] 0.20
 0.04 0.43
 0.07
318_3 [H]EKLKKIGQKIKNFFQKLVPQPEQ[NH2] 0.25
 0.04 0.33
 0.01
318_4 [H]KLKKIGQKIKNFFQKLVPQPEQ[NH2] 25 25
318_5 [H]LKKIGQKIKNFFQKLVPQPEQ[NH2] 0.21
 0.01 0.30
 0.00
318_6 [H]KKIGQKIKNFFQKLVPQPEQ[NH2] 0.25
 0.03 0.40
 0.03
318_7 [H]KIGQKIKNFFQKLVPQPEQ[NH2] 0.24
 0.02 0.35
 0.02
318_8 [H]IGQKIKNFFQKLVPQPEQ[NH2] 0.30
 0.04 0.46
 0.06
318_9 [H]GQKIKNFFQKLVPQPEQ[NH2] 0.43
 0.13 0.58
 0.14
318_10 [H]QKIKNFFQKLVPQPEQ[NH2] 1.50
 0.50 10.30
 3.90
318_11 [H]KIKNFFQKLVPQPEQ[NH2] 0.30
 0.04 1.74
 0.73
318_12 [H]IKNFFQKLVPQPEQ[NH2] 0.78
 0.25 4.50
 1.50
318_13 [H]KNFFQKLVPQPEQ[NH2] 8.37
 4.52 18.33
 1.67
318_14 [H]NFFQKLVPQPEQ[NH2] 8.40
 4.18 20.00
 5.00
318_15 [H]FFQKLVPQPEQ[NH2] 12.00
 4.16 25
318_16 [H]FQKLVPQPEQ[NH2] 25 25
318_17 [H]QKLVPQPEQ[NH2] 25 25
318_18 [H]KLVPQPEQ[NH2] 25 25
318_19 [H]LVPQPEQ[NH2] 25 25
318_20 [H]VPQPEQ[NH2] 25 25
318_21 [H]PQPEQ[NH2] 25 25
318_22 [H]QPEQ[NH2] 25 25
318_23 [H]PEQ[NH2] 18.75
 4.27 25
318_24 [H]KIGEKLKKIGQKIKNFFQKLVPQPE[OH] 0.33
 0.03 0.55
 0.09
318_25 [H]KIGEKLKKIGQKIKNFFQKLVPQP[OH] 0.40
 0.07 0.60
 0.15
318_26 [H]KIGEKLKKIGQKIKNFFQKLVPQ[OH] 0.25
 0.04 0.48
 0.14
318_27 [H]KIGEKLKKIGQKIKNFFQKLVP[OH] 0.28
 0.02 0.31
 0.04
318_28 [H]KIGEKLKKIGQKIKNFFQKLV[OH] 10.90
 2.34 13.75
 3.06
318_29 [H]KIGEKLKKIGQKIKNFFQKL[OH] 0.28
 0.04 0.38
 0.01
318_30 [H]KIGEKLKKIGQKIKNFFQK[OH] 0.30
 0.00 1.70
 0.30
318_31 [H]KIGEKLKKIGQKIKNFFQ[OH] 0.23
 0.05 0.47
 0.06
318_32 [H]KIGEKLKKIGQKIKNFF[OH] 0.22
 0.03 0.40
 0.00
318_33 [H]KIGEKLKKIGQKIKNF[OH] 0.28
 0.03 0.59
 0.12
318_34 [H]KIGEKLKKIGQKIKN[OH] 0.29
 0.02 0.53
 0.16
318_35 [H]KIGEKLKKIGQKIK[OH] 0.30
 0.00 25
318_36 [H]KIGEKLKKIGQKI[OH] 0.44
 0.09 0.70
 0.10
318_37 [H]KIGEKLKKIGQK[OH] 0.36
 0.08 0.80
 0.00
318_38 [H]KIGEKLKKIGQ[OH] 3.50
 1.00 5.83
 0.17
318_39 [H]KIGEKLKKIG[OH] 4.17
 3.71 6.00
 0.00
318_40 [H]KIGEKLKKI[OH] 4.00
 1.15 8.00
 1.50
318_41 [H]KIGEKLKK[OH] 12.38
 4.32 25
318_42 [H]KIGEKLK[OH] 25 25
318_43 [H]KIGEKL[OH] 25 25
318_44 [H]KIGEK[OH] 25 25
318_45 [H]KIGE[OH] 25 25
318_46 [H]KIG[OH] 25 25
318_47 [H]IGEKLKKIGQKIKNFFQKLVPQPE[OH] 0.28
 0.02 0.33
 0.03
318_48 [H]GEKLKKIGQKIKNFFQKLVPQP[OH] 0.25
 0.03 0.45
 0.05
318_49 [H]EKLKKIGQKIKNFFQKLVPQ[OH] 0.25
 0.05 0.28
 0.05
318_50 [H]KLKKIGQKIKNFFQKLVP[OH] 0.24
 0.06 0.38
 0.08
318_51 [H]LKKIGQKIKNFFQKLV[OH] 25 25
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iofilm activity can be quantified by CFU determination as well as
by using the metabolic dye CTB.
AS10 acts synergistically with caspofungin and amphoteri-
cin B. First, we determined the activity of AS10 against pregrown
C. albicans biofilms. The BEC-2 was higher than 400 M. This
indicates that AS10 cannot eradicate mature C. albicans biofilms
and hence displays antibiofilm activity against C. albicans only
during the biofilm formation phase. Also, the OSIP108 biofilm-
inhibiting peptide cannot eradicate mature biofilms. However,
OSIP108 acts synergistically with commonly used antifungals
such as caspofungin and amphotericin B (39). Therefore, we
checked whether AS10 acts synergistically with caspofungin, am-
photericin B, and miconazole in a biofilm eradication assay. To
this end, pregrownC. albicans biofilmswere incubatedwith 2-fold
serial dilutions of AS10 in combinationwith 2-fold serial dilutions
of caspofungin or amphotericin B. The BEC-2 of caspofungin and
amphotericin B in the presence of AS10was determined (Table 4).
In addition, FICI values were calculated for each combination by
checkerboard analysis to assess potential synergy. Our results
show that, although AS10 alone displays no effect on mature bio-
films, different concentrations of AS10 (0.39 to 1.56 M) act syn-
ergistically with caspofungin and amphotericin B with regard to
eradication ofmature biofilms (FICI 0.5; Table 4). The presence
of AS10 decreased the BEC-2 of caspofungin and amphotericin B
up to 8.6- and 5-fold, respectively. In contrast, AS10 does not act
synergistically with miconazole (results not shown). Moreover,
the synergy of AS10 with caspofungin and amphotericin B was
also determined based on the more stringent BEC-5 parameter
(Table 4). Similar results were obtained with these data. In the
presence ofAS10 (0.39 to 1.56M), theBEC-5 of caspofungin and
amphotericin B was reduced up to 8- and 5-fold, with FICI
values 0.5.Hence, combination therapy using coadministration
of AS10 and caspofungin or amphotericin B might be effective in
curing biofilm-associated infections. The current repertoire of an-
tifungal agents is limited, and some of the commonly used anti-
fungal agents have toxic side effects. As such, combination ther-
apy, in which the activity of existing antifungal agents is enhanced
by the presence of AS10, may allow lowering of the effective dose
of amphotericin B or caspofungin, thereby reducing their toxic
side effects and/or economic costs (22). Furthermore, combina-
tion therapy could potentially limit the incidence of resistance to
antifungal agents.
AS10 prevents biofilm formation in a mixed C. albicans and
S. epidermidis biofilm. In nature, most biofilms are composed of
two or more species. These mixed biofilms are clinically relevant,
as nosocomial C. albicans bloodstream infections are often poly-
TABLE 3 C. albicans biofilm-inhibitory activity of P318 sequence variants
Peptide Sequence BIC-2 (M)
 SEM BIC-5 (M)
 SEM
318_AS1 [H]AIGEKLKKIGQKIKNFFQKLVPQPEQ[NH2] 0.36
 0.05 0.53
 0.08
318_AS2 [H]KAGEKLKKIGQKIKNFFQKLVPQPEQ[NH2] 0.16
 0.03 0.24
 0.04
318_AS3 [H]KIAEKLKKIGQKIKNFFQKLVPQPEQ[NH2] 0.15
 0.03 0.23
 0.03
318_AS4 [H]KIGAKLKKIGQKIKNFFQKLVPQPEQ[NH2] 0.15
 0.03 0.24
 0.02
318_AS5 [H]KIGEALKKIGQKIKNFFQKLVPQPEQ[NH2] 0.09
 0.01 0.16
 0.02
318_AS6 [H]KIGEKAKKIGQKIKNFFQKLVPQPEQ[NH2] 0.16
 0.03 0.25
 0.03
318_AS8 [H]KIGEKLKAIGQKIKNFFQKLVPQPEQ[NH2] 0.15
 0.03 0.28
 0.03
318_AS9 [H]KIGEKLKKAGQKIKNFFQKLVPQPEQ[NH2] 0.18
 0.01 0.25
 0.03
318_AS10 [H]KIGEKLKKIAQKIKNFFQKLVPQPEQ[NH2] 0.12
 0.02 0.21
 0.01
318_AS12 [H]KIGEKLKKIGQAIKNFFQKLVPQPEQ[NH2] 0.16
 0.01 0.26
 0.02
318_AS13 [H]KIGEKLKKIGQKAKNFFQKLVPQPEQ[NH2] 0.12
 0.01 0.22
 0.03
318_AS14 [H]KIGEKLKKIGQKIANFFQKLVPQPEQ[NH2] 0.85
 0.10 1.50
 0.00
318_AS16 [H]KIGEKLKKIGQKIKNAFQKLVPQPEQ[NH2] 0.13
 0.03 0.23
 0.03
318_AS17 [H]KIGEKLKKIGQKIKNFAQKLVPQPEQ[NH2] 0.14
 0.01 0.28
 0.03
318_AS18 [H]KIGEKLKKIGQKIKNFFAKLVPQPEQ[NH2] 0.15
 0.00 0.20
 0.00
318_AS19 [H]KIGEKLKKIGQKIKNFFQALVPQPEQ[NH2] 0.18
 0.01 0.30
 0.00
318_AS20 [H]KIGEKLKKIGQKIKNFFQKAVPQPEQ[NH2] 0.23
 0.01 0.35
 0.00
318_AS21 [H]KIGEKLKKIGQKIKNFFQKLAPQPEQ[NH2] 0.12
 0.02 0.19
 0.01
318_AS22 [H]KIGEKLKKIGQKIKNFFQKLVAQPEQ[NH2] 0.12
 0.02 0.25
 0.02
318_AS23 [H]KIGEKLKKIGQKIKNFFQKLVPAPEQ[NH2] 0.12
 0.02 0.23
 0.03
318_AS24 [H]KIGEKLKKIGQKIKNFFQKLVPQAEQ[NH2] 0.15
 0.02 0.23
 0.03
318_AS25 [H]KIGEKLKKIGQKIKNFFQKLVPQPAQ[NH2] 0.13
 0.01 0.21
 0.01
318_AS26 [H]KIGEKLKKIGQKIKNFFQKLVPQPEA[NH2] 0.15
 0.00 0.25
 0.03
FIG 1 AS10 prevents C. albicans biofilm formation on titanium disks. C.
albicans biofilms were grown in RPMI 1640 on titanium disks for 24 h in the
absence (MilliQ water control) or presence of 12.5 and 6.25 MAS10 during
adhesion and biofilm formation. Afterward, biofilms were washed twice and
quantified using CFU determination. The graph represents the means of the
results of three biologically independent repeats
 SEMwith duplicate repeats
per experiment. Statistical analysis was performed using one-way ANOVA
with Bonferroni’s multiple-comparison test (**, P 0.01; ***, P 0.001). Ti,
titanium.
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microbial (45) and interactions between different species in a
mixed biofilm can alter their respective susceptibilities to specific
antibiotics (46–48). We investigated whether AS10 can prevent
biofilm formation of C. albicans in a mixed yeast-bacterium bio-
film, i.e., one composed ofC. albicans and S. epidermidis. AS10 not
only reduced the number of C. albicans cells in the mixed biofilm
but also considerably reduced the number of S. epidermidis cells,
indicating that the biofilm-inhibitory effect of AS10 is not limited
to C. albicans but can also be directed against bacterial biofilm
formation. In a mixed biofilm, the BIC-2 for C. albicans is 6.25
M,which is significantly higher than its BIC-2 in a single-species
biofilm (BIC-2  0.22 M) (Fig. 2). This could be due to the
higher initial cell density and prolonged incubation time of the
mixed biofilm protocol or due to the presence of S. epidermidis.
AS10 has a broad spectrum of biofilm-inhibitory activity.As
AS10 inhibits biofilmdevelopment of theGram-positive species S.
epidermidis in amixed biofilm, we checked whether AS10 can also
inhibit biofilm formation of other bacteria, such as different
Gram-negative species, including E. coli, P. aeruginosa, and P. gin-
givalis. AS10 inhibited biofilm formation of all bacterial species
tested (BIC-2 2.6 to 20.3 M; Table 5).
The observation that AS10 shows C. albicans-specific antibio-
film activity might imply that its potential clinical use is limited.
However, as C. albicans remains the predominant fungal patho-
gen in humans (49–54), AS10 remains a valuable peptide in tack-
ling C. albicans-associated infections. C. albicans is the dominant
Candida species forming biofilms on voice prostheses (infection
rate, 50% to 100%) and dentures (infection rate, 5% to 10%) (4).
As AS10 can also inhibit formation of bacterial andmixed-species
biofilms, this clearly broadens its application spectrum. For exam-
ple, coinfection of C. albicans and S. epidermidis is a well-known
problem in neonatal intensive care units and increases mortality
compared to single-species infections (55, 56). The two species
can form mixed biofilms on central vascular catheters, which are
regularly used on these infants during the first weeks after birth
and can be an important source for infection (55). Therefore,
although clinical use of AS10 seems potentially limited, there are
several applications where AS10 can still be valuable.
AS10does not affect the viability and functionality of human
osteoblasts, mesenchymal stromal cells, or endothelial cells. In
light of its putative application as an antibiofilm coating onmedical
devices and implants, we assessed possible effects of AS10 on various
human cell types important for implant fixation. To obtain correct
integration of the implant into the bone, the coating has to be non-
toxic for the surrounding cells and should not impede the function-
ality of the cells. Therefore, both the viability and the functionality of
various human cell types, including osteoblasts, mesenchymal stro-
mal cells, and endothelial cells, were determined in the presence of
12.5MAS10. AS10 did not significantly affect the viability of osteo-
blasts (83.7%
 8.8% survival compared to 90.2%
 3% [control]),
mesenchymal stromal cells (87.8% 
 2.7% survival compared to
96.8%
 2.4% [control]), and endothelial cells (99.6%
 1.1% sur-
vival compared to 99.6%
 0.6%[control]) after 6 days. Survivalwas
strongly reduced by the positive-control phenol (0.05%), a known
cytotoxic substance, and was 38.2% 
 11.5% for osteoblasts,
12.9% 
 15.1% for mesenchymal stromal cells, and 0% 
 0% for
endothelial cells.
Furthermore, AS10 did not decrease calcium deposition of
TABLE 4 Synergistic activity of AS10 with caspofungin or amphotericin B against C. albicans biofilmsa
AS10
concn
(M)
Caspofungin plus AS10 Amphotericin B plus AS10 Caspofungin plus AS10 Amphotericin B plus AS10
BEC-2 CAS
(M)

SEM P value
Fold
change FICI
BEC-2
AmB
(M)

SEM P value
Fold
change FICI
BEC-5 CAS
(M)

SEM P value
Fold
change FICI
BEC-5
AmB
(M)

SEM P value
Fold
change FICI
0 0.65
 0.17 NA NA NA 0.67
 0.17 NA NA NA 0.70
 0.10 NA NA NA 1.23
 0.28 NA NA NA
1.56 0.08
 0.03 0.005 8.63 0.120 0.13
 0.02 0.007 5.03 0.203 0.09
 0.01 0.003 8.00 0.129 0.24
 0.03 0.004 5.14 0.171
0.78 0.09
 0.03 0.006 7.40 0.137 0.12
 0.01 0.006 5.58 0.181 0.12
 0.00 0.004 5.83 0.173 0.21
 0.04 0.003 5.97 0.158
0.39 0.15
 0.01 0.011 4.26 0.236 0.29
 0.02 0.043 2.34 0.429 0.28
 0.01 0.013 2.55 0.394 0.50
 0.03 0.021 2.48 0.245
a AmB, amphotericin B; CAS, caspofungin; NA, not applicable. One-way ANOVA with Bonferroni’s multiple-comparison test was used to compare the BEC-2 and BEC-5 of CAS
and AMB in the absence of AS10 with their BEC-2 and BEC-5 in the presence of the indicated AS10 concentrations.
FIG 2 AS10 inhibits the formation of a mixed biofilm. Mixed biofilms of C.
albicans and S. epidermidiswere grown in RPMI 1640medium in the presence
or absence of AS10 during adhesion (24 h) and biofilm development (an ad-
ditional 48 h). Afterward, biofilm cells were quantified by plating on YPD agar
plates containing 100 mg/liter ampicillin and TSA plates containing 25 mg/
liter amphotericin B to determine fungal and bacterial CFU, respectively. The
percentages of C. albicans (filled diamonds) and S. epidermidis (filled circles)
biofilm cells, relative to the control treatment (0.5%MilliQ water), are shown.
Data represent the means and SEM of the results of three independent exper-
iments, each consisting of two technical repeats.
TABLE 5 Inhibitory activity of AS10 against biofilms from different
bacterial species
Bacterial species BIC-2
 SEM
C. albicans SC5314 0.22
 0.02
C. albicans DAY286 0.32
 0.05
C. albicans CAF2–1 0.67
 0.18
E. coli 2.6
 0.22
P. aeruginosa 5.4
 0.018
P. gingivalis 20.3
 6.42
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mesenchymal stromal cells (0.179
 0.015 ngCa2/gDNAcom-
pared to 0.167 
 0.0045 ng Ca2/g DNA [control]) or osteo-
blasts (0.223 
 0.008 ng Ca2/g DNA compared to 0.237 

0.020 ng Ca2/ng DNA [control]), indicating no negative effects
on the osteogenic-differentiation potential. In addition, incuba-
tion with AS10 for 8 h did not reduce the potential of endothelial
cells to form tubular structures as no significant differences in the
average tube lengths of endothelial cells were observed in the pres-
ence of 12.5MAS10 (113
 17 pixels for AS10-treated endothe-
lial cells compared to 125
 11 pixels for the control treatment).
In contrast, treatment with 0.05% phenol significantly reduced
the average tube formation after 8 h to 87
 8 pixels (Fig. 3). These
results show that AS10 is not toxic for human osteoblasts, mesen-
chymal stromal cells, and endothelial cells and does not affect the
functionality of these human cells, indicating that AS10 might be
suitable for coating on implants to prevent biofilm formation.
Conclusions. Based on a structure-activity relationship study
of the antibiofilm activity of a CRAMP-derived peptide, we iden-
tified AS10 as the most potent antibiofilm peptide which inhibits
biofilm formation of C. albicans and various Gram-positive and
Gram-negative bacteria and acts synergistically with caspofungin
or amphotericin B against mature C. albicans biofilms. As AS10
has a broad spectrum of biofilm-inhibitory activity but does not
have adverse effects on the viability or functionality of diverse
human cell types involved in bone formation, AS10 is an interest-
ing lead molecule for the development of a biofilm-preventive
coating for implants.
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